Compare CTNT & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | MBIO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.3M |
| IPO Year | 2023 | 2023 |
| Metric | CTNT | MBIO |
|---|---|---|
| Price | $2.69 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 168.3M | 33.8K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.74 | ★ 98.99 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,536.00 | N/A |
| Revenue This Year | $42.49 | N/A |
| Revenue Next Year | $22.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.02 | $0.53 |
| 52 Week High | $4.21 | $7.00 |
| Indicator | CTNT | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 33.11 |
| Support Level | $1.48 | $0.53 |
| Resistance Level | $4.21 | $0.80 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 64.30 | 10.40 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.